aTYR PHARMA (ATYR) FCF Margin (2019 - 2025)

aTYR PHARMA's (ATYR) quarterly FCF Margin came in at 10796.32% in Q3 2025, down 13.28% on a QoQ basis from 9530.64% in Q1 2024.

aTYR PHARMA (ATYR) FCF Margin (2019 - 2025) Analysis & Trends

aTYR PHARMA (ATYR) has 6 years of FCF Margin data on file, last reported at 10796.32% in Q3 2025.

Quarterly FCF Margin changed N/A year-over-year to 10796.32% in Q3 2025, while the trailing twelve-month figure through Mar 2026 was 31209.47% (changed N/A YoY) and the FY2025 annual result came in at 32664.74%, down 322474.0% from the prior year.
FCF Margin eased to 10796.32% in Q3 2025, from 9530.64% in the prior quarter.
In the past five years, FCF Margin ranged from a high of 110.61% in Q4 2022 to a low of 10796.32% in Q3 2025.
A 4-year average of 5825.82% and a median of 6198.18% in 2023 frame the typical range for FCF Margin.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	13.35%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	22.62%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	41.07%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	70.82%
10	aTYR PHARMA	49.54 Mn	-7.87 Mn	-	-

Download Data